Research Topics
| J YahalomSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphomaGaurav D Shah
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:4730-5. 2007....
Does radiotherapy still have a place in Hodgkin lymphoma?Joachim Yahalom
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Hematol Malig Rep 4:117-24. 2009..This review discusses controversial issues regarding RT, the studies that have addressed them, the new indications for integrating RT, and the safety of minimizing the radiation field and dose...
Favorable early-stage Hodgkin lymphomaJoachim Yahalom
Radiation Oncology in Medicine Department, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Natl Compr Canc Netw 4:233-40. 2006..Although combined modality is the standard preferred treatment for favorable disease, radiation therapy alone or chemotherapy alone could be considered under special circumstances or as part of an investigational protocol...
Role of radiation therapy in Hodgkin's lymphomaJoachim Yahalom
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
Cancer J 15:155-60. 2009..Short chemotherapy supplemented with mini-radiotherapy constitutes a highly effective and safe treatment of HL, particularly in early stages...
Long-term cardiac and pulmonary complications of cancer therapyJoachim Yahalom
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Hematol Oncol Clin North Am 22:305-18, vii. 2008..Potential preventive measures for high-risk patients are of increasing interest but remain experimental...
Changing role and decreasing size: current trends in radiotherapy for Hodgkin's diseaseJoachim Yahalom
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 4:415-23. 2002..The new principles of integrating radiotherapy into a combined-modality regimen for HD at different prognostic stages are reviewed here, along with the effect of this new role on radiation field size and design...
The involved field is back: issues in delineating the radiation field in Hodgkin's diseaseJ Yahalom
Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Ann Oncol 13:79-83. 2002..In this manuscript we review the comeback of the involved field, address design questions and offer field borders for common disease sites...
Long-term cardiac and pulmonary complications of cancer therapyJoachim Yahalom
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Heart Fail Clin 7:403-11. 2011..Potential preventive measures for high-risk patients are of increasing interest but remain experimental...
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10165, USA
J Clin Oncol 26:1858-64. 2008..To analyze outcome, prognostic factors, and toxicities in patients with diffuse large-cell lymphoma (DLCL) who received involved-field radiotherapy (IFRT) before high-dose chemotherapy with autologous stem-cell rescue (ASCR)...
Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveatJoachim Yahalom
Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Leuk Lymphoma 48:1667-9. 2007
Radiation therapy in the treatment of lymphomaJ Yahalom
Memorial Sloan Kettering Cancer Center, and Radiation Oncology in Medicine, Cornell University Medical College, New York, NY, USA
Curr Opin Oncol 11:370-4. 1999..Preliminary data suggest that even in an advanced-stage, intermediate-grade, adjuvant radiotherapy to bulky sites may improve outcome. This issue merits further study...
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceS M Edwards-Bennett
Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Oncol 21:574-81. 2010..We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data...
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphomaT Kewalramani
Department of Medicine, Lymphoma and Hematology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Bone Marrow Transplant 32:673-9. 2003....
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin
Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
Blood 102:1989-96. 2003..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens...
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphomaB S Hoppe
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Bone Marrow Transplant 43:941-8. 2009..006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further...
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamideC S Portlock
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Oncol 15:1495-503. 2004..The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy program developed to improve outcome in advanced, aggressive non-Hodgkin's lymphomas...
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphomaC H Moskowitz
Lymphoma and Hematology Services, Department of Medicine, and Departments of Radiotherapy, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 17:3776-85. 1999....
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Leuk Lymphoma 46:541-7. 2005..Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies...
Treatment for primary CNS lymphoma: the next stepL E Abrey
Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 18:3144-50. 2000..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
Delayed neurotoxicity in primary central nervous system lymphomaAntonio M P Omuro
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Arch Neurol 62:1595-600. 2005....
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-upAntonio M P Omuro
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Neurology 64:69-74. 2005..First relapse and neurotoxicity within 2 years of diagnosis seem to be critical for predicting long-term outcomes...
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphomaAndreas F Hottinger
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Neurology 69:1178-82. 2007..Consequently, patients are often treated with chemotherapy alone, and WBRT is deferred until relapse...
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic modelLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:5711-5. 2006....
Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patientsKathryn Beal
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 106:2652-6. 2006....
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)Benjamin D Rosenbluth
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 65:1185-91. 2006..We studied clinical responses of MCL patients treated with involved-field radiation therapy (IFRT) predominantly for local control and/or palliation...
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapyDenise D Correa
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Neurooncol 91:315-21. 2009..There was no significant cognitive decline up to 24 months post-chemotherapy and reduced-dose WBRT in this group of PCNSL patients, however, difficulties in Verbal Memory and Motor speed persisted over the follow-up period...
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imagingCraig H Moskowitz
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Br J Haematol 148:890-7. 2010..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patientsJurgen Rademaker
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1270 York Ave, New York, NY 10021, USA
AJR Am J Roentgenol 191:32-7. 2008....
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz
Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
Br J Haematol 146:158-63. 2009..Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months...
Imaging of late complications from mantle field radiation in lymphoma patientsSandra Brennan
Department of Radiology, Memorial Sloan Kettering Cancer Center, Weil Medical College of Cornell University, New York, NY 10021, USA
Radiol Clin North Am 46:419-30, x. 2008..Dedicated imaging approaches have been developed to evaluate late radiation effects on these structures...
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphomaKaryn A Goodman
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 26:5240-7. 2008....
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapyMeltem Ekenel
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 113:1025-31. 2008..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's diseaseCraig H Moskowitz
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, PO Box 350, New York, NY 10021, USA
Br J Haematol 124:645-52. 2004..001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy...
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's diseaseCarol S Portlock
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
Br J Haematol 125:701-8. 2004..CD20(+) cHD is a poor prognostic factor for TTF and OS. All cHD cases should be immunophenotyped for CD20. A large prospective trial is needed to confirm these findings...
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin diseaseDavid J Straus
Memorial Sloan Kettering Cancer Center, SR 441B Box 406, 1275 York Ave, New York, NY 10021, USA
Blood 104:3483-9. 2004..Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial...
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin
Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 130:691-9. 2005....
Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapyAriela Noy
Lymphoma Disease Management Team and Laboratroy of Molecular Hemato Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:3768-72. 2005..We have previously demonstrated long-term pathologic remission after involved-field radiotherapy therapy (IFRT). We determined molecular remission status by clonotypic polymerase chain reaction (PCR)...
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 103:3684-8. 2004..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT...
Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cellsShoshana Paglin
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 65:11061-70. 2005..Taken together, these experiments show that radiation-induced inhibition of rapamycin-sensitive pathway in MCF-7 cells causes changes in mitochondria metabolism, development of autophagy, and an overall decrease in cell survival...
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 casesK P Beal
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Ann Oncol 16:473-80. 2005..This study suggests that imaging with FDG-PET scans is useful for both initial staging and follow-up of patients with extranodal MZL...
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphomaIgor T Gavrilovic
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:4570-4. 2006..For older patients, it appears to be reasonable to defer whole brain radiotherapy in an effort to minimize treatment-related neurotoxicity...
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphomaTarun Kewalramani
Hematology Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 134:202-7. 2006..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL...
Radiation-induced salivary gland tumors: a report of 18 cases and a review of the literatureKathryn P Beal
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer J 9:467-71. 2003..This series also suggests an increased risk for developing malignant (versus benign) SGT after radiation exposure...
Intensity-modulated tangential beam irradiation of the intact breastL Hong
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 44:1155-64. 1999..To evaluate the potential benefits of intensity modulated tangential beams in the irradiation of the intact breast...
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphomaA D Zelenetz
Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York 10021, USA
Ann Oncol 14:i5-10. 2003..This resulted in an increased complete remission rate. Additional follow-up is necessary to determine if this improvement in the complete remission rate will confer an increase in the overall survival following SCT...
Retinopathy in survivors of primary central nervous system lymphomaSean A Grimm
Memorial Sloan-Kettering Cancer Center, Department of Neurology, 1275 York Avenue, New York, NY 10021, USA
Neurology 67:2060-2. 2006..We describe five patients with long-term primary CNS lymphoma who were diagnosed with retinopathy several years after treatment with chemotherapy and WBRT...
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancersKenneth Offit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:3813-9. 2002..We next sought to determine the frequency of ATM variants in patients with Hodgkin's lymphoma, regardless of coexisting BC, compared with healthy volunteers...
Intensity-modulated radiotherapy for lymphoma involving the mediastinumKaryn A Goodman
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 62:198-206. 2005..Additional follow-up is necessary to determine whether improvements in dose delivery affect long-term morbidity and disease control...
Extranodal MALT Lymphoma of the Right Triceps Muscle following Influenza Vaccine Injection: A Rare Case with an Interesting PresentationS M Edwards-Bennett
Department of Radiation Oncology, H Lee, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
ISRN Hematol 2011:617293. 2011..She was treated with single modality, involved field radiation therapy (IFRT) to 4000 cGy in 20 fractions with excellent response and no evidence of disease after one year followup...
A novel response of cancer cells to radiation involves autophagy and formation of acidic vesiclesS Paglin
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 61:439-44. 2001....
Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic reviewJustin E Bekelman
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Radiat Oncol Biol Phys 73:492-8. 2009..Although radiotherapy (RT) is an important component of curative therapy for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), we postulated that RT reporting may be inadequate in Phase III HL and NHL trials...
Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphomaStefan K Barta
Department of Medicine, St. Luke's Roosevelt Hospital Center, New York, NY, USA
Clin Lymphoma Myeloma 7:77-82. 2006..There is no established approach to the management of paraneoplastic cholestasis. We postulate that single-modality radiation therapy alone should be considered a valid treatment alternative in early-stage HL with idiopathic cholestasis...
Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published dataDev R Puri
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 71:1425-35. 2008..We set out to analyze our recent experience in treating PDMZL and reviewed the limited published data available...
Radiation treatment planning techniques for lymphoma of the stomachCesar Della Biancia
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 62:745-51. 2005..Using 4-field 3DCRT markedly decreases the kidney dose. The addition of IMRT led to further incremental improvements in the left kidney and liver dose in selected patients...
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort studyElena B Elkin
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 29:2466-73. 2011..To compare characteristics and outcomes of breast cancer in women with and without a history of radiation therapy (RT) for Hodgkin's lymphoma (HL)...
Breast cancer after Hodgkin disease: hope for a safer cureJoachim Yahalom
JAMA 290:529-31. 2003
Hodgkin disease/lymphomaRichard T Hoppe
Stanford Comprehensive Cancer Center, USA
J Natl Compr Canc Netw 6:594-622. 2008
Non-Hodgkin's lymphomasAndrew D Zelenetz
J Natl Compr Canc Netw 6:356-421. 2008
Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphomaJoachim Yahalom
J Clin Oncol 24:544-8. 2006
Advances in biology, diagnostics, and treatment of Hodgkin's diseaseRalf Kuppers
Institute for Cell Biology, Tumor Research, University of Duisburg Essen, Germany
Biol Blood Marrow Transplant 12:66-76. 2006....
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancerDonald A Podoloff
J Natl Compr Canc Netw 5:S1-S22; quiz S23-2. 2007..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
Pathways that regulate autophagy and their role in mediating tumor response to treatmentShoshana Paglin
The Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
Autophagy 2:291-3. 2006..Future analysis of the interrelationship among these events and the role each of them plays in cell survival following radiation will increase our ability to employ the mTOR pathway in anti-cancer therapy...
Multiple myeloma. Clinical practice guidelines in oncologyKenneth C Anderson
J Natl Compr Canc Netw 5:118-47. 2007
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncologyAndrew D Zelenetz
J Natl Compr Canc Netw 4:258-310. 2006
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002Andres J M Ferreri
Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, 20132, Milan, Italy
J Clin Oncol 21:2407-14. 2003..This article summarizes the contents of the Workshop, analyzes the current knowledge on the most relevant biologic and clinical issues in PCNSL, and focuses on fundamental challenges to be addressed in future studies...
Clinical practice. Superior vena cava syndrome with malignant causesLynn D Wilson
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
N Engl J Med 356:1862-9. 2007
The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic CohortPhilip Bretsky
University of Southern California Norris Comprehensive Cancer Center, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
Cancer Epidemiol Biomarkers Prev 12:733-8. 2003..Although a single missense variant (L546V) appeared to act as a modest predictor of risk, the remaining variants were no more common in breast cancer cases as compared with controls...
Cancer Survivorship. PrefaceLois B Travis
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human ServicesNational Institutes of Health, Bethesda, MD, USA
Hematol Oncol Clin North Am 22:xi-xii. 2008
Cancer survivorship: facing forwardLois B Travis
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, National Institutes of Health, Bethesda, MD, USA
Hematol Oncol Clin North Am 22:365-71, ix. 2008..In this article, the authors briefly review the history of the efforts that served to coalesce efforts to champion survivorship research, identify future challenges, and provide a perspective on future recommendations...
Hodgkin disease/lymphoma. Clinical practice guidelines in oncologyRichard T Hoppe
J Natl Compr Canc Netw 4:210-30. 2006
